메뉴 바로가기 본문 바로가기

TEST ITEMS

THE GENERATION DIAGNOSTIC SYSTEM

iFOB

Colorectal cancer is the third most common cancer in the world[1], with about 1 million new cases and more than 500, 000 deaths per year. Screening method for colorectal cancer include the immuno-chromatography fecal occult blood (iFOB) test, barium enema, sigmoidoscopy and colonoscopy[2]. Large randomized controlled trials have shown that iFOB screening can result in decreased colorectal cancer mortality[3,4]. The standard FOB test uses the chemical Guaiac, which is sensitive to Hb peroxidase activity. However, the standard Guaiac-FOB test has low sensitivity to clinically significant colorectal neoplasis and has low specificity due to its non-specificity for human Hb[5,6]. To overcome these potential problems in immunochemical test, ichroma™ iFOB uses specific monoclonal antibodies against human Hb as capture and detection buffer[7]

References

  • 1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2020: Cancer incidence, motality and Prevalence worldwide. IARC CancerBase no. 5, version 2.0. Lyon, France: IARC Pr; 2004.
  • 2. Arnold CN, Goel A, Blum HE, Boland CR. Molecular pathogenesis of colorectal cancer: implications for molecular diagnosis. Cancer 2005;104:2035-2047.
  • 3. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing mortality from colorectal cancer by scrrning for fecal occult blood. Minnesota Colon Cancer Control study. N Engl J Med 1993;328:1365-1371
  • 4. Kronborg O, Fenger C, Olden J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with fecal occult blood test. Lancet 1996;384:1467-1471.
  • 5. Hardcastle JD, Chamberlain J, Robinson MH, Moss SM, Amar SS, Balfour TW, et al. Randomised controlled trial of fecal occult blood screening for colorectal cancer. Lancet 1996;348:1472-1477.
  • 6. Rozen P, Waked A, Vilkin A, et al. Evaluation of a desk top instrument for the automated development and immunochemical quantification of fecal occult blood. Med Sci Moint 2006;12(6):MT27-32.
  • 7. Oh SW, Moon JD, Park SY, et al. Evaluation of fluorescence hsCRP immunoassay for point of care testing. Clin Chim Acta 2005;356:172-177.

ichroma™

Compatible Device ichroma™ I/II
Detection Range 25~1,000 ng/mL
Sample Type Feces
CV <10%
Comparability 0.971
Reaction Time 10Min

Product News